Teprotumumab Recombinant Human Monoclonal Antibody, Invitrogen™

Description

• Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles
• Store at 2 to 8 °C for one week
• Store at -20 to -80 °C for twelve months from the date of receipt
• Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor
• 8 Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received &quotebreakthrough therapy&quote designation from the FDA in 20163 and was approved by the FDA in January 2020 for the treatment of TED
• 7 Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries - teprotumumab is the first pharmaceutical ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.